İntravezikal Bacillus Calmette-Guerin (BCG) İntoleransı Gelişmiş Hastada Nadir Bir Olgu: Otoimmün Miyopati

Yıl 2023, Cilt: 7 Sayı: 2, 258 - 261, 31.08.2023

Gökhan Çeker , Bülent Akduman

https://doi.org/10.29058/mjwbs.1270107

Öz

Amaç: Kasa invaze olmayan mesane kanserinin tedavisinde kullanılan intravezikal Bacillus Calmette-
Guerin (BCG)’ye karşı intolerans gelişen hastada gözlenen otoimmün miyopati olgusunu sunuyoruz.
Olgu: Kasa invaze olmayan mesane kanserinin tedavisinde kullanılan intravezikal BCG mesanede
otoimmüniteyi artırarak etki etmektedir. Bu artan otoimmünite bazen lokal veya sistemik reaksiyonlara
neden olabilmektedir. Bu olgu sunumunda, 61 yaşında bir erkek hastada idame BCG tedavisinin ilk
dozu alındıktan sonra intolerans gelişti ve daha sonra tedavisine devam edilemedi. BCG intoleransı
gelişiminden 1 ay sonra hasta sol kuadriseps femoris bölgesinde konvülsif ağrılı kramplar ve kas
seğirmeleri şikâyeti ile kliniğimize başvurdu. Hastanın anamnezi, elektromiyografi (EMG) sonuçları,
kreatin kinaz yüksekliği ve diğer laboratuvar verileri birlikte değerlendirildiğinde BCG ile tetiklenen
otoimmün miyopati geliştiği düşünüldü. Bu nedenle steroid tedavisi başlandı ve hasta yedi hafta sonra
sağlığına kavuştu. Bu olgu mesane tümörü için intravezikal BCG tedavisi alan hastada görülen nadir bir
otoimmün miyopati olgusudur.
Sonuç: BCG ile ilişkili otoimmün miyopati olgusu son derece nadirdir. Bu klinikten şüphelenildiğinde
steroid tedavisinin zaman geçirilmeden başlanılmasında fayda vardır.

Anahtar Kelimeler

Bacillus Calmette-Guerin, mesane kanseri, kasa invaze olmayan mesane kanseri, miyopati

Destekleyen Kurum

Yok

A Rare Case Seen in a Patient with Intravesical Bacillus Calmette-Guerin (BCG) Intolerance: Autoimmune Myopathy

Öz

Aim: We present a case of autoimmune myopathy observed in a patient who developed intolerance
to intravesical Bacillus Calmette-Guerin (BCG), which is used in the treatment of non-muscle invasive
bladder cancer.
Case: Intravesical BCG, which is used for the treatment of non-muscle invasive bladder cancer, probably
effects by increasing autoimmunity in the bladder. This increased autoimmunity sometimes causes local
or systemic reactions. In this case report, we would like to present a 61-year-old male patient who
developed intolerance while taking the first dose of maintenance BCG, and then on-going treatment
was stopped. The patient had convulsive painful cramps and muscle twitches in the left quadriceps
femoris region one month later BCG intolerance. When the patient’s anamnesis, electromyography
(EMG) results, elevated Creatine Kinase value and other laboratory data were evaluated together, BCG
triggered autoimmune myopathy was considered. Therefore, steroid treatment was started and the
patient recovered seven weeks later. This is a rare case of autoimmune myopathy in a patient who
received intravesical BCG therapy for a bladder tumor.
Conclusion: The case of BCG-associated autoimmune myopathy is extremely rare. When this situation
is suspected, it is beneficial to start steroid treatment without delay.

Anahtar Kelimeler

Bacillus Calmette-Guerin, bladder cancer, non-muscle invasive bladder cancer, myopathy

Kaynakça

• 1. International Agency for Research on Cancer, W.H.O., 2021. Estimated number of new cases in 2020, worldwide, both sexes, all ages. Cancer Today. https://gco. iarc. fr/today/onlineanalysis- table.
• 2. Gontero P, Compérat EM, Escrig Dominguez JL, Liedberg F, Mariappan P, Masson-Lecomte A, Mostafid AH, van Rhijn BWG, Rouprét M, Seisen T, Shariat SF, Xylinas EN. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) – 2023 edition.
• 3. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Publ Gr 2014;11:153–62. doi:10.1038/ nrurol.2014.15.
• 4. Green DB, Kawashima A, Menias CO, Tanaka T, Redelman- Sidi G, Bhalla S, Shah R, King BF. Complications of intravesical BCG immunotherapy for bladder cancer. Radiographics 2019;39(1):80-94.
• 5. Luca S, Mihaescu T. History of BCG Vaccine. Maedica (Bucur) 2013;8(1):53-58
• 6. Bloomberg SD, Brosman SA, Hausman MS, Cohen A, Battenberg JD. The effects of BCG on the dog bladder. Invest Urol 1975;12:423-427.
• 7. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-182.
• 8. Alhunaidi O, Zlotta AR. The use of intravesical BCG in urothelial carcinoma of the bladder. Ecancermedicalscience 2019;13:905.
• 9. Orbach H, Tanay A. Vaccines as a trigger for myopathies. Lupus 2009;18:1213-1216.
• 10. Kåss E, Straume S, Munthe E. Dermatomyosıtıs after BCG vaccination. Lancet 1978;311:772.
• 11. Sabio JM, Vargas-Hitos JA, Jiménez-Alonso J. Paraneoplastic dermatomyositis associated with bladder cancer. Lupus 2006;15:619-620.
• 12. Hissako Sumida D, Yamamoto Chiba F, Sara de Lima Coutinho Mattera M. Inflammatory muscle diseases. Muscle Cells- Recent Adv Futur Perspect, IntechOpen; 2020.
• 13. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015;372:1734-1747